• Hengrui Pharma will present 64 research results at the ESMO congress in Madrid on Oct. 23-27, 2026.
• Phase 3 HORIZON-Breast06 results will assess trastuzumab rezetecan in advanced breast cancer with low HER2 expression.
• HERON-Lung01 will report interim results comparing ruzaltatug rezetecan with platinum-based chemotherapy in advanced EGFR-mutated lung cancer progressing following EGFR inhibitor treatment.
• China accepted ruzaltatug rezetecan’s marketing application for review in July 2026; the drug also received US FDA fast-track designation.
• Phase 2 results will cover KRAS G12D inhibitor HRS-4642 with chemotherapy, with or without adebrelimab, as perioperative treatment for KRAS G12D-mutated pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: FR76423) on October 21, 2026, and is solely responsible for the information contained therein.